Audentes Therapeutics, Inc
BOLD
BOLD was delisted on the 14th of January, 2020.
139 hedge funds and large institutions have $1.71B invested in Audentes Therapeutics, Inc in 2019 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 49 increasing their positions, 41 reducing their positions, and 14 closing their positions.
228% more call options, than puts
Call options by funds: $3.87M | Put options by funds: $1.18M
100% more funds holding in top 10
Funds holding in top 10: 4 → 8 (+4)
93% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 14
87% more capital invested
Capital invested by funds: $913M → $1.71B (+$794M)
20% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 41
10% more funds holding
Funds holding: 126 → 139 (+13)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GGHC
Gilder Gagnon Howe & Co
New York
|
+$41.9M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$23.1M |
| 3 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$17.2M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
+$12.4M |
| 5 |
Jennison Associates
New York
|
+$9.24M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$28.4M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$20.5M |
| 3 |
NC
Nexthera Capital
New York
|
-$14.7M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$14.7M |
| 5 |
Morgan Stanley
New York
|
-$13M |
BOLD Hedge Fund Activity: Q1 2019 in Review
139 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Audentes Therapeutics, Inc (BOLD) for Q1 2019, worth a combined $1.71B — up 87% from $913M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new BOLD positions and 14 closed out — a net gain of 13 holders — while 49 added to existing stakes and 41 trimmed.
The largest buyer was Gilder Gagnon Howe & Co, adding an estimated $41.9M. The largest seller was PFM Health Sciences, cutting an estimated $28.4M.
- 139 institutional investors held Audentes Therapeutics, Inc (BOLD) as of Q1 2019, up from 126 in Q4 2018.
- Funds reported $1.71B of Audentes Therapeutics, Inc stock for Q1 2019, up 87% quarter-over-quarter.
- 27 funds opened new Audentes Therapeutics, Inc positions in Q1 2019 and 14 closed out, a net change of +13 holders.
- The largest Audentes Therapeutics, Inc buyer in Q1 2019 was Gilder Gagnon Howe & Co, an estimated $41.9M added.
- The largest Audentes Therapeutics, Inc seller in Q1 2019 was PFM Health Sciences, an estimated $28.4M sold.
Based on aggregated 13F filings for Q1 2019.